β-Cyclodextrin Hydrate is a cyclic sugar compound first characterized in the 1930s, derived from starch by enzymatic processing. It forms a ring-shaped structure capable of encapsulating hydrophobic molecules, improving their solubility and stability. Widely used in pharmaceuticals, food, and cosmetics, β-Cyclodextrin Hydrate enhances the delivery of poorly water-soluble compounds and is generally regarded as safe for topical and oral applications.
BRAND NAMES
Cavamax® W7 – widely used in pharmaceuticals and food.
Captisol® – a chemically modified β-cyclodextrin for drug formulations.
Kleptose® – used in pharmaceuticals and nutraceuticals.
Cyclocap® – for inclusion complexes in food and cosmetic products.
MECHANISM OF ACTION
β-Cyclodxtrin Hydrate forms inclusion complexes by trapping hydrophobic molecules in its ring-shaped cavity, while its outer surface remains water-soluble. This enhances the solubility, stability, and bioavailability of compounds without chemically altering them.
PHARMACOKINETICS
Absorption
β-Cyclodextrin Hydrate is poorly absorbed in the gastrointestinal tract due to its large cyclic structure. Most of it passes unchanged into the colon, where it can be partially broken down by intestinal microbiota into glucose. Its ability to improve the solubility of other compounds can indirectly enhance the absorption of encapsulated drugs.
Distribution
β-Cyclodextrin Hydrate distributes poorly after oral administration, with less than 10% of the dose reaching blood and tissues. Most remains in the gut, while small amounts reach organs like the liver and kidneys before being metabolized or excreted.
Metabolism
β-Cyclodextrin Hydrate is minimally metabolized in the human body. Most of the orally administered dose remains intact in the gastrointestinal tract, where intestinal microbiota partially break it down into glucose. Only small amounts undergo systemic metabolism before being excreted.
Excretion
β-Cyclodextrin Hydrate is primarily excreted unchanged in the feces, since most of it is not absorbed from the gastrointestinal tract. Small amounts that enter the bloodstream are eliminated via urine, with overall systemic excretion representing only a minor fraction of the administered dose.
PHARMACODYNAMICS
β-Cyclodextrin Hydrate is pharmacologically inert on its own and does not produce direct therapeutic effects. Its primary action is physicochemical: forming inclusion complexes with hydrophobic molecules, which enhances their solubility, stability, and bioavailability, thereby improving the efficacy of co-administered drugs or compounds.
ADMINISTRATION
β-Cyclodextrin Hydrate can be administered orally, topically, or by injection depending on the formulation. Orally, it is used to improve the solubility and absorption of poorly water-soluble drugs. Parenteral and topical forms are typically employed in pharmaceuticals and cosmetic products to enhance stability and bioavailability of active compounds.
DOSAGE AND STRENGTH
β-Cyclodextrin Hydrate does not have a standard therapeutic dose since it is pharmacologically inert. Its amount varies by formulation, typically ranging from 2% to 50% w/w in pharmaceutical or nutraceutical products, depending on the drug or compound being solubilized and the intended route of administration.
FOOD INTERACTIONS
β-Cyclodextrin Hydrate is generally considered safe with no significant food interactions. However, because it can form complexes with lipophilic compounds, it may alter the absorption of certain dietary fats or fat-soluble vitamins when consumed in large amounts, potentially reducing their bioavailability.
DRUG INTERACTIONS
β-Cyclodextrin Hydrate is pharmacologically inert but can interact with drugs by forming inclusion complexes. This can increase solubility and bioavailability of poorly water-soluble drugs, but may also alter absorption or reduce effectiveness of certain lipophilic medications if not properly formulated.
CONTRAINDICATIONS
β-Cyclodextrin Hydrate is generally well tolerated and considered safe, but it is contraindicated in individuals with known hypersensitivity to cyclodextrins. Caution is advised in patients with severe gastrointestinal disorders or impaired renal function, as excessive doses may cause osmotic diarrhea or accumulation.
SIDE EFFECTS
β-Cyclodextrin Hydrate is generally well tolerated, but high doses may cause mild gastrointestinal effects such as bloating, diarrhea, or nausea. Topical use is usually safe, though rare allergic reactions like skin irritation or rash can occur in sensitive individuals.
TOXICITY
β-Cyclodextrin Hydrate has low toxicity in humans. Oral or topical exposure is generally safe, with adverse effects occurring only at very high doses. Animal studies indicate a high LD₅₀, and it does not accumulate significantly in tissues, making it considered non-toxic under normal use.
